Oral Soluble Guanylate Cyclase Stimulators Associated With Reduced Hospitalizations for Heart Failure

May 15-17, 2021; Virtual
In meta-analysis of 8 randomized placebo-controlled clinical trials, addition of oral sGC stimulators to guideline-directed medical therapy for heart failure reduced risk of hospitalization for heart failure vs placebo; net adverse events not significantly increased over placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 291 KB
Released: June 29, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck

Related Content

From Clinical Care Options (CCO), new data in managing heart failure from ACC 2021

Lee R. Goldberg, MD, MPH, FACC James Udelson, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: July 28, 2021 Expired: July 27, 2022

Dr. Lee R. Goldberg discusses key studies from ACC 2021 that will impact heart failure management, as reported by Clinical Care Options (CCO)

Lee R. Goldberg, MD, MPH, FACC Released: July 15, 2021

Latest data on empagliflozin in routine care of patients with type 2 diabetes from ACC 2021 reported by Clinical Care Options (CCO)

Released: June 30, 2021

Meta-analysis of 62 clinical trials with SGLT2 inhibitors showed significantly increased rates of overall infections, genital infections, and diabetic ketoacidosis from AAC 2021 reported by Clinical Care Options (CCO)

Released: June 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue